Reuptake of L-DOPA-Derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter

To determine the role of norepinephrine transporter in reuptake Of LDOPA-derived extracellular DA in the DA-denervated Parkinsonian striatum, we examined extracellular DA levels in the striatum of 6-hydroxyDA-lesioned rats that received L-DOPA (50 mg/kg with 12.5 mg/kg of benserazide) and L-DOPA plus desipramine (25 mg/kg), a selective norepinephrine reuptake inhibitor, using in vivo microdialysis. The pretreatment with desipramine increased levels of extracellular DA derived from administrated L-DOPA in the DA-denervated striatum. This study provides evidence that L-DOPA-derived DA is taken up by the norepinephrine transporter, instead of the dopamine transporter, in the striatum with doparninergic denervation. This result suggests that the norepinephrine transporter could be a promising target in the treatment for Parkinson's disease.